SEARCH

SEARCH BY CITATION

References

  • 1
    Hirayama H, Sugano M, Abe N, Yonemoch H, Makino N: Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 2001; 77: 7579.
  • 2
    Martens FM, Visseren FL, Lemay J, de Konong EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolinediones. Drugs 2002; 62: 14631480.
  • 3
    Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 115.
  • 4
    Hollenberg NK: Considerations for management of fluid dynamic issues associated with thiazolinediones. Am J Med 2003; 115(Suppl 8A): 111S115S.
  • 5
    Peterson RL, Waggoner AD, Schetchman KB, Meyer T, Gropler RJ, et al.: Alterations in left ventricular structure and function in young healthy obese women. J Am Coll Cardiol 2004; 43: 13991404.
  • 6
    Piccoli A, Brunani A, Savia G, Pillon L, Favaro E et al.: Discriminating between body fat and fluid overload changes in the obese adults using bioimpedance vector analysis. Int J Obes 1998; 22: 97104.
  • 7
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA Teacher DF, et al.: Homeostasis model assessment, insulin resistance and ß cell function from fasting plasma glucose and insulin concentration in human. Diabetologia 1985; 28: 412419.
  • 8
    Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613618.
  • 9
    Sutton MSJ, Rendell M, Dandona P, Dole JF, Murphy K, et al.: Rosiglitazone clinical trias study froup. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 20582064.
  • 10
    Kiryluk K, Isom R: Thiazolidinediones and fluid retention. Kidney Int 2007; 72: 762768.
  • 11
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al.: Thiazolidinediones use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003; 108: 29411948.
  • 12
    Kim SH, Abbassi F, Chu JW, McLaughlin TL, Lamendola C, et al.: Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005; 54: 24472452.
  • 13
    Avandia (rosiglitazone maleate) tablets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2007 (package insert).
  • 14
    Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006; 20: 12031205.
  • 15
    Pickavence LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH: Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999; 128: 15701576.
  • 16
    Rennings AJM, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006; 29: 581587.
  • 17
    Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels—a systemic review. Blood Press 2006; 15: 135150.
  • 18
    Amà R, Segers P, Roosens C, Claessens T, Verdonck P, et al.: The effects of load on systolic mitral annular velocity by tissue Doppler imaging. Anesth Analg 2004; 99: 332338.
  • 19
    Gondoni LA, Titon AM, Silvestri G, Nibbio F, Taronna O, et al.: Short term effects of physical exercise and low calorie diet on left ventricular function in obese subjects: a tissue Doppler study. Nutr Metab Cardiovasc Dis 2007; 17: 358364.
  • 20
    Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Matthew WR, et al.: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005; 146: 53415349.
  • 21
    Kelly AS, Bank AJ: The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 2007; 21: 326334.